Literature DB >> 535181

Metabolism of human beta 1H: studies in man and experimental animals.

J A Charlesworth, D M Scott, B A Pussell, D K Peters.   

Abstract

Metabolic studies were performed with a purified, functionally-active preparation of human beta 1H. In seven normal human subjects, the half-life ranged from 66--87 hr with fractional catabolic rates (FCR) of 1.04--1.63%/hr. Synthesis rates were 0.22--0.57 mg/kg/hr and extravascular distribution ratios were 0.34--0.67. There was evidence of extra-vascular catabolism in each subject. In sixteen patients with immunological disease four showed hypercatabolism of beta 1H. However, three patients with C3 mephritis factor (NeF) had normal beta 1H turnover despite profound reduction in C3 concentration; it is suggested that the reaction of beta 1H with the C3b. Bb convertase exposes it to a catabolic site and that in the NeF patients the NeF stabilized convertase prevents such exposure. Studies of the acute phase response were carried out in nine patients following elective surgery, with C-reactive protein (CRP) used as the control protein: six patients showed no rise in beta 1H levels and three showed a small (20%) rise whereas all exhibited a gross rise in CRP. Pre-incubation of 125I- beta 1H with NHS, with NHS in the presence of NeF and with C3b+C3b 1NA caused no change in beta 1H turnover in animals despite demonstrable total C3 conversion with the NeF.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 535181      PMCID: PMC1537924     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  18 in total

1.  ANTIGEN-ANTIBODY CROSSED ELECTROPHORESIS.

Authors:  C B LAURELL
Journal:  Anal Biochem       Date:  1965-02       Impact factor: 3.365

2.  The theory of tracer experiments with 131I-labelled plasma proteins.

Authors:  C M MATTHEWS
Journal:  Phys Med Biol       Date:  1957-07       Impact factor: 3.609

3.  A method of trace iodination of proteins for immunologic studies.

Authors:  P J McConahey; F J Dixon
Journal:  Int Arch Allergy Appl Immunol       Date:  1966

4.  Metabolism of the fifth component of complement, and its relation to metabolism of the third component, in patients with complement activation.

Authors:  J G Sissons; J Liebowitch; N Amos; D K Peters
Journal:  J Clin Invest       Date:  1977-04       Impact factor: 14.808

5.  Value of immune-complex assays in diagnosis and management.

Authors:  B A Pussell; C M Lockwood; D M Scott; A J Pinching; D K Peters
Journal:  Lancet       Date:  1978-08-12       Impact factor: 79.321

6.  C3b inactivator of man. II. Fragments produced by C3b inactivator cleavage of cell-bound or fluid phase C3b.

Authors:  S Ruddy; K F Austen
Journal:  J Immunol       Date:  1971-09       Impact factor: 5.422

7.  Comparative clinical study of protein SAP (amyloid P component) and C-reactive protein in serum.

Authors:  M B Pepys; A C Dash; R E Markham; H C Thomas; B D Williams; A Petrie
Journal:  Clin Exp Immunol       Date:  1978-04       Impact factor: 4.330

8.  Modulation of the alternative complement pathways by beta 1 H globulin.

Authors:  K Whaley; S Ruddy
Journal:  J Exp Med       Date:  1976-11-02       Impact factor: 14.307

9.  Interaction of beta1H globulin with cell-bound C3b: quantitative analysis of binding and influence of alternative pathway components on binding.

Authors:  D H Conrad; J R Carlo; S Ruddy
Journal:  J Exp Med       Date:  1978-06-01       Impact factor: 14.307

10.  Properdin: binding to C3b and stabilization of the C3b-dependent C3 convertase.

Authors:  D T Fearon; K F Austen
Journal:  J Exp Med       Date:  1975-10-01       Impact factor: 14.307

View more
  11 in total

1.  Interactions of complement proteins C1q and factor H with lipid A and Escherichia coli: further evidence that factor H regulates the classical complement pathway.

Authors:  Lee Aun Tan; Andrew C Yang; Uday Kishore; Robert B Sim
Journal:  Protein Cell       Date:  2011-05-15       Impact factor: 14.870

2.  Hypocomplementaemia due to a genetic deficiency of beta 1H globulin.

Authors:  R A Thompson; M H Winterborn
Journal:  Clin Exp Immunol       Date:  1981-10       Impact factor: 4.330

3.  Partial H (beta 1H) deficiency and glomerulonephritis in two families.

Authors:  R J Wyatt; B A Julian; A Weinstein; N F Rothfield; R H McLean
Journal:  J Clin Immunol       Date:  1982-04       Impact factor: 8.317

4.  Complement inhibitors and immunoconglutinins in ulcerative colitis and Crohn's disease.

Authors:  B J Potter; D J Brown; A Watson; D P Jewell
Journal:  Gut       Date:  1980-12       Impact factor: 23.059

5.  Complement activation by phospholipids: the interplay of factor H and C1q.

Authors:  Lee Aun Tan; Bingbin Yu; Francis C J Sim; Uday Kishore; Robert B Sim
Journal:  Protein Cell       Date:  2010-12-10       Impact factor: 14.870

6.  Human fibronectin metabolism.

Authors:  B A Pussell; P W Peake; M A Brown; J A Charlesworth
Journal:  J Clin Invest       Date:  1985-07       Impact factor: 14.808

7.  The kinetics and distribution of C9 and SC5b-9 in vivo: effects of complement activation.

Authors:  J D Greenstein; P W Peake; J A Charlesworth
Journal:  Clin Exp Immunol       Date:  1995-04       Impact factor: 4.330

8.  Evaluation of alternative pathway and factor B haemolytic activities in patients with systemic lupus erythematosus: correlations with the alternative pathway regulatory proteins.

Authors:  M T Aguado; L H Perrin; R Ramirez; P A Miescher; P H Lambert
Journal:  Clin Exp Immunol       Date:  1980-12       Impact factor: 4.330

9.  Purification and structural studies on the complement-system control protein beta 1H (Factor H).

Authors:  R B Sim; R G DiScipio
Journal:  Biochem J       Date:  1982-08-01       Impact factor: 3.857

10.  Hereditary porcine membranoproliferative glomerulonephritis type II is caused by factor H deficiency.

Authors:  K Høgåsen; J H Jansen; T E Mollnes; J Hovdenes; M Harboe
Journal:  J Clin Invest       Date:  1995-03       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.